To our knowledge, our study is the first within melanoma that has evaluated a digital analysis algorithm to quantify WSI CD8+ TIL density and derived a predictive value associated with response to front-line anti-PD-1 therapy in a real-world setting. The gene discussed is CD8A; the disease is melanoma.